Cargando…

The improvement of pulmonary artery pressure after bosentan therapy in patients with β-thalassemia and Doppler-defined pulmonary arterial hypertension

INTRODUCTION: Pulmonary arterial hypertension (PAH) is relatively prevalent in patients with thalassemia. PAH treatment is necessary as the prevalence of Doppler-estimated PAH and the resultant mortality is high in such patients. MATERIALS AND METHODS: This study aimed at evaluating the effect of bo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Karami, Hossein, Darvishi-Khezri, Hadi, Kosaryan, Mehrnoush, Akbarzadeh, Rosetta, Dabirian, Mojdeh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Case Series
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301293/ https://www.ncbi.nlm.nih.gov/pubmed/30588128 http://dx.doi.org/10.2147/IMCRJ.S180602

Ejemplares similares

Treatment Status of Patients with B-Thalassemia Major in Northern Iran: Thalassemia Registry System
por: KOSARYAN, Mehrnoush, et al.
Publicado: (2019)

Combination Iron Chelation Therapy with Deferiprone and Deferasirox in Iron-Overloaded Patients with Transfusion-Dependent β-Thalassemia Major
por: Karami, Hossein, et al.
Publicado: (2017)

Silymarin therapy and improvement of cardiac outcome in patients with β-thalassemia major
por: Khezri, Hadi Darvishi, et al.
Publicado: (2016)

Administration of Intravenous Zoledronic Acid Every 3 Months vs. Annually in β-thalassemia Patients with Low Bone Mineral Density: a Retrospective Comparison of Efficacy
por: Darvishi-Khezri, Hadi, et al.
Publicado: (2018)

Moderate to severe liver siderosis and raised AST are independent risk factors for vitamin D insufficiency in β-thalassemia patients
por: Darvishi-Khezri, Hadi, et al.
Publicado: (2020)

Cardiac Structural and Functional Changes Evaluated by Transthoracic and Tissue Doppler Echocardiography in Adult Patients with Sickle Cell Disease
por: Dabirian, Mojdeh, et al.
Publicado: (2017)

Ferritin thresholds for cardiac and liver hemosiderosis in β-thalassemia patients: a diagnostic accuracy study
por: Darvishi-Khezri, Hadi, et al.
Publicado: (2022)

Potential Effects of Silymarin and Its Flavonolignan Components in Patients with β-Thalassemia Major: A Comprehensive Review in 2015
por: Darvishi Khezri, Hadi, et al.
Publicado: (2016)

Amlodipine: Can act as an antioxidant in patients with transfusion‐dependent β‐thalassemia? A double‐blind, controlled, crossover trial
por: Darvishi‐Khezri, Hadi, et al.
Publicado: (2022)

Review of bosentan in the management of pulmonary arterial hypertension
por: Gabbay, Eli, et al.
Publicado: (2007)

Safety and tolerability of bosentan in the management of pulmonary arterial hypertension
por: Roberts, Kari E, et al.
Publicado: (2009)

The Role of Doppler Imaging in the Assessment of Right Ventricular Function: a Case-control Study of Acute Inferior Wall Infarction
por: Dabirian, Mojdeh, et al.
Publicado: (2018)

Ebselen: A promising therapy protecting cardiomyocytes from excess iron in iron-overloaded thalassemia patients
por: Ghazaiean, Mobin, et al.
Publicado: (2023)

Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient
por: Valerio, Christopher J, et al.
Publicado: (2009)

Cost Effectiveness of Bosentan for Pulmonary Arterial Hypertension: A Systematic Review
por: You, Ruxu, et al.
Publicado: (2018)

Bosentan for Treatment of Pediatric Idiopathic Pulmonary Arterial Hypertension: State-of-the-Art
por: Wang, Yuchen, et al.
Publicado: (2019)

Doppler-defined pulmonary hypertension in β-thalassemia major in Kurdistan, Iraq
por: Mohammad, Ameen M., et al.
Publicado: (2020)

Genetics and genomics of pulmonary arterial hypertension
por: Morrell, Nicholas W., et al.
Publicado: (2019)

Exertional dyspnoea in pulmonary arterial hypertension
por: Dumitrescu, Daniel, et al.
Publicado: (2017)

Sex and gender in pulmonary arterial hypertension
por: Cheron, Céline, et al.
Publicado: (2021)

Extramedullary Hematopoiesis Presenting as a Right Adrenal Mass in a Patient With Beta Thalassemia
por: Karami, Hossein, et al.
Publicado: (2014)

Beneficial and Adverse Effects of Bosentan Treatment in Korean Patients With Pulmonary Artery Hypertension
por: Sohn, Dae-Won, et al.
Publicado: (2009)

Meta-analysis of randomized controlled trials of bosentan for treatment of pulmonary arterial hypertension
por: Lee, Young Ho, et al.
Publicado: (2013)

Lower Doses of Bosentan in Combination With Sildenafil Might be Beneficial in Pulmonary Arterial Hypertension
por: Amin, Ahmad, et al.
Publicado: (2015)

Chronic dosing with metformin plus bosentan decreases in vitro pulmonary artery contraction from isolated arteries in adults with pulmonary hypertension
por: Liao, Shutan, et al.
Publicado: (2019)

Risk stratification and medical therapy of pulmonary arterial hypertension
por: Galiè, Nazzareno, et al.
Publicado: (2019)

Bosentan for pulmonary hypertension secondary to idiopathic pulmonary fibrosis
por: Onda, Naomi, et al.
Publicado: (2014)

Clinical trial design and new therapies for pulmonary arterial hypertension
por: Sitbon, Olivier, et al.
Publicado: (2019)

Transition from Ambrisentan to Bosentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study
por: Gong, Su-Gang, et al.
Publicado: (2018)

Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial
por: Vizza, Carmine Dario, et al.
Publicado: (2017)

Prospective clinical assessment of patients with pulmonary arterial hypertension switched from bosentan to macitentan (POTENT)
por: Aldalaan, Abdullah M., et al.
Publicado: (2022)

Transition from Bosentan to Ambrisentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study
por: Chen, Jingyuan, et al.
Publicado: (2021)

Monocrotaline-Induced Pulmonary Arterial Hypertension and Bosentan Treatment in Rats: Focus on Plasma and Erythrocyte Parameters
por: Jasenovec, Tomas, et al.
Publicado: (2022)

Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management
por: Rosenzweig, Erika B., et al.
Publicado: (2019)

Beneficial effects of long-term treatment with bosentan on the development of pulmonary arterial hypertension in patients with systemic sclerosis
por: Murdaca, Giuseppe, et al.
Publicado: (2016)

Safety and efficacy of transitioning from the combination of bosentan and sildenafil to alternative therapy in patients with pulmonary arterial hypertension
por: Verlinden, Nathan J., et al.
Publicado: (2020)

Two trade names of deferasirox (Osveral® and Exjade®) in reduction of iron overload parameters in major beta-thalassemia patients: A randomized open labeled clinical trial
por: Rafati, Mohammadreza, et al.
Publicado: (2022)

Bosentan and sildenafil in the treatment of HIV-associated pulmonary hypertension
por: Chinello, Pierangelo, et al.
Publicado: (2011)

Transient Use of Oral Bosentan Can Be an Additional Option to Reduce Pulmonary Arterial Hypertension in a Patient with Severe Pulmonary Arterial Hypertension Associated with Atrial Septal Defect
por: Park, Yong Kyu, et al.
Publicado: (2011)

Effect of acetylsalicylic acid on thalassemia with pulmonary arterial hypertension
por: Chueamuangphan, Nonlawan, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_dh26vnikmtcgfuhnk8tsrb82qv